Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 316 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omeprazole Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects

NCT00655746
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib + Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

NCT03333824
View directory record Official record
Conditions
Solid Tumours
Interventions
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 3 Interventional

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241514
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
19
States / cities
Tucson, Arizona • Anaheim, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2011 · Synced Oct 17, 2026, 12:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 17, 2026, 12:02 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Impact of Proton Pump Inhibitors on the Fecal Microbiome

NCT01822977
View directory record Official record
Conditions
Healthy, Clostridium Difficile Infection
Interventions
omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers

NCT05497557
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Omeprazole, Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 17, 2026, 12:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

NCT05517928
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Lactobacillus rhamnosus GG, Placebo
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 17, 2026, 12:02 AM EDT
Terminated Phase 3 Interventional Results available

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

NCT00664209
View directory record Official record
Conditions
Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
Interventions
clartihromycin, amoxicillin, and omeprazole, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 3 Interventional

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05267613
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Nexium 20mg, Nexium 10mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer

NCT04865731
View directory record Official record
Conditions
Cancer of the Head and Neck
Interventions
Dermaprazole, Aquaphor
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 4 Interventional

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

NCT00428701
View directory record Official record
Conditions
Gastric Ulcer
Interventions
Esomeprazole Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Newark, Delaware • Shreveport, Louisiana • Hershey, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 17, 2026, 12:02 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer

NCT02013453
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Omeprazole, Carboplatin, 5FU, Paclitaxel, Pemetrexed
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 17, 2026, 12:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

NCT01094275
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel 75mg, Omeprazole 20mg
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 17, 2026, 12:02 AM EDT
Not listed Phase 1 Interventional

The Effect of Nexium on Transmucosal Esophageal Leak

NCT00216788
View directory record Official record
Conditions
Reflux, Esophagitis, Barrett's Esophagus
Interventions
Esomeprazole (Nexium) 40 mg/day
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 17, 2026, 12:02 AM EDT
Terminated Phase 1 Interventional Results available

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

NCT01142128
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 17, 2026, 12:02 AM EDT
Withdrawn Phase 4 Interventional

The Effect of NSAIDs After a Rotator Cuff Repair Surgery.

NCT02153177
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Rotator cuff repair, Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole, Hydrocodone/Acetaminophen
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 4 Interventional

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

NCT00410592
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 69 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Anaheim, California • Orange, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 3 Interventional

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241553
View directory record Official record
Conditions
NSAIDs, Upper GI Symptoms
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
31
States / cities
Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, lapatinib plus esomeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

NCT00442052
View directory record Official record
Conditions
Healthy
Interventions
aspirin, omeprazole
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oral OKT3 for the Treatment of Active Ulcerative Colitis

NCT01287195
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Oral OKT3, Omeprazole
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 17, 2026, 12:02 AM EDT
Completed Phase 2 Interventional

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

NCT00002682
View directory record Official record
Conditions
Lymphoma
Interventions
Amoxicillin, Bismuth Subsalicylate, Clarithromycin, Metronidazole Hydrochloride, Omeprazole, Tetracycline Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 17, 2026, 12:02 AM EDT